ASX:NXSNext Science Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Next Science Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$1.62 -0.02 (-1.22 %) (As of 05/13/2020) Add Compare Share Today's RangeA$1.60Now: A$1.62▼A$1.6950-Day RangeA$1.62MA: A$1.62▼A$1.6252-Week RangeA$1.00Now: A$1.62▼A$4.29Volume86,564 shsAverage VolumeN/AMarket Capitalization$293.61 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Next Science Limited, a medical technology company, develops and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria. The company develops its products using its Xbio Technology platform. It offers SurgX, an innovative surgical gel designed to reduce superficial surgical site infections and protect wound tissue to facilitate natural healing; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. The company also provides TorrentX, an antimicrobial wound wash; and BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. In addition, it is developing acne gel; middle ear wash for use in patients with chronic ear infections; minimally invasive surgical lavage to replace a saline wound lavage; nasal packing stent for use in recovery from nasal surgery; adhesion barrier that is implanted in surgery field to prevent internal adhesion; and soft coating for implants. Further, the company develops tropical treatments for school sores, infected atopic dermatitis, and fungal nails; tropical preventative treatment for keloid scarring; and products for bacterial vaginosis, as well as over the counter products, such as mouthwash. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Next Science. Previous Next 2.5 Community Rank Outperform VotesNext Science has received 7 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNext Science has received 7 “underperform” votes. (Add your “underperform” vote.)Community SentimentNext Science has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Next Science and other stocks. Vote “Outperform” if you believe NXS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NXS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNext Science does not currently pay a dividend.Dividend GrowthNext Science does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Next Science insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Next Science is -18.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Next Science is -18.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNext Science has a P/B Ratio of 15.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolASX:NXS Previous Symbol CUSIPN/A CIKN/A Webwww.nextscience.com Phone61 2 8607 5124Debt Debt-to-Equity Ratio2.49 Current Ratio11.23 Quick Ratio10.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.06 million Price / Sales72.30 Cash FlowA$0.09 per share Price / Cash Flow17.23 Book ValueA$0.11 per share Price / Book15.14Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares181,242,000Market Cap$293.61 million Next Earnings DateN/A OptionableNot Optionable Receive NXS News and Ratings via Email Sign-up to receive the latest news and ratings for NXS and its competitors with MarketBeat's FREE daily newsletter. Next Science (ASX:NXS) Frequently Asked Questions How has Next Science's stock been impacted by COVID-19 (Coronavirus)? Next Science's stock was trading at A$1.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NXS stock has decreased by 3.9% and is now trading at A$1.62. View which stocks have been most impacted by Coronavirus. Has Next Science been receiving favorable news coverage? Headlines about NXS stock have trended negative on Saturday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Next Science earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Next Science. Who are some of Next Science's key competitors? Some companies that are related to Next Science include Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), Hexo (HEXO), OrganiGram (OGI), HEXO (HEXO), Amryt Pharma (AMYT), ICC Labs (ICC), Benchmark (BMK), ESSA Pharma (EPI), Probiotec (PBP), Green Organic Dutchman (TGOD), Shield Therapeutics (STX), WeedMD (WMD) and cbdMD (YCBD). View all competitors. What other stocks do shareholders of Next Science own? Based on aggregate information from My MarketBeat watchlists, some companies that other Next Science investors own include Abbott Laboratories (ABT), AbbVie (ABBV), Perth Mint Physical Gold ETF (AAAU), Argo Investments (ARG), Arcturus Therapeutics (ARCT), Appen (APX), Afterpay Touch Group (APT), Advanced Micro Devices (AMD), Altium (ALU) and Alector (ALEC). Who are Next Science's key executives? Next Science's management team includes the following people: Ms. Judith Mitchell M.B.A., MD, CEO & DirectorDr. Matthew Myntti, Founder & CTOMs. Jacqueline Butler CA (ICAEW), Chief Financial OfficerMr. Jon Swanson, Chief Operating OfficerMr. Don Ayers, VP of Sales & Marketing What is Next Science's stock symbol? Next Science trades on the ASX under the ticker symbol "NXS." What is Next Science's stock price today? One share of NXS stock can currently be purchased for approximately A$1.62. How big of a company is Next Science? Next Science has a market capitalization of $293.61 million and generates $4.06 million in revenue each year. What is Next Science's official website? The official website for Next Science is www.nextscience.com. How can I contact Next Science? The company can be reached via phone at 61 2 8607 5124. This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
